Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...
Medpage Today on MSN1d
Pulled Myeloma Drug Improves Survival in Trial
A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...
Next-generation treatment protects against progression in some patients with advanced breast cancer
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...
Pancreatic cancer patient survival doubled with high dose of common vitamin, study finds
The researchers found that administering 75 grams of vitamin C three times a week doubled overall survival rates of patients ...
Renal & Urology News1d
Survival Up With Nivolumab + Ipilimumab Versus Chemo for Metastatic CRC
Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer ...
BioSpace1d
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence ...
The American Journal of Managed Care9h
Treatment Combinations Based in Immune Checkpoint Inhibitors Provide Survival Benefits in CRC
Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...
IN8bio (NASDAQ:INAB) Reports Continued Progression-Free Survival in Phase 1 Trial at ASH Annual Meeting
IN8bio, Inc., a clinical-stage biopharmaceutical company focusing on innovative gamma-delta T cell therapies, recently shared updated data on December 10, 2024. This data demonstrated sustained ...
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase ...
The American Journal of Managed Care2d
Cilta-cel Leads to Prolonged Progression-Free Survival in Multiple Myeloma
Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients ...
Study finds increased survival with nivolumab plus ipilimumab vs. chemo for metastatic colorectal cancer
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
J&J : DARZALEX FASPRO Regimens Improve MRD Negativity, Survival In Newly Diagnosed Multiple Myeloma
Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve ...